

FLEURY S.A.
Public Held Company
Company Taxpayer's ID (CNPJ) 60.840.055/0001-31
Company Registry (NIRE) 35.300.197.534

NOTICE TO THE MARKET

Sixth Issuance of Debentures of Grupo Fleury

Fleury S.A. ("Fleury Group" or "Company") informs its shareholders and the market in general that, on this date, it has ended its 6th issuance of simple, non-convertible, unsecured debentures, in three series ("Debentures"), for public distribution with restricted placement efforts ("Restricted Offer"), pursuant to CVM Instruction No. 476, of January 16, 2009, as amended.

1,000,000 (one million) Debentures were issued, with a nominal unit value of R\$ 1,000.00 (one thousand Brazilian reais), totaling R\$ 1,000,000,000.00 (one billion Brazilian reais), divided in three series, the First Series of R\$ 250 million, the Second of R\$ 375 million and the Third of R\$ 375 million, maturing on July 8, 2025, July 8, 2026 and July 8, 2028, respectively.

This is the first issuance of Debentures by a company of the Healthcare sector in Brazil with ESG (Environmental, Social and Governance) goals, being connected to the Company's growth acceleration strategy and the ambition to build a sustainable healthcare ecosystem with integrated solutions benefiting patients, physicians, HMOs and society in general, in line with the best ESG practices.

This fundraising had a second opinion report prepared by SITAWI Finanças do Bem, with the objective to ensure the classification of the issuance as ESG Performance-Linked Bonds (Sustainability-Linked Bond), following the Sustainability-Linked Bond Principles of the International Capital Markets Association.

This is the Company's first ESG issuance and its goals are in line with Grupo Fleury's Strategic Plan regarding the focus on environmental conservation, sustainable development and healthcare democratization, with a high relevance and materiality for the businesses of Grupo Fleury, which, pursuant to the terms of the indenture of the Issuance of Debentures:

- Reduction of the generation of biological waste rate to 0.0115 kg/test until December 2023 in 14.12% and to 0.0107 kg/test until December 2025 in 20.54%;
- Access to healthcare through Saúde iD for 250,000 clients from social classes C, D and E until June 2024 and a total of 1,000,000 clients from social classes C, D and E until June 2026.

The net funds raised through the Restricted Offer will be used for general corporate uses, such as such as working capital reinforcement and extension of the Company's liabilities. The main terms and conditions of the Restricted Offer are summarized below:

- The Debentures will be entitled to remuneration equivalent to 100% (one hundred percent) of the DI Rate (Interbank Deposits), plus a spread equivalent to (i) 1.35% per year in relation to the First Series Debentures; (ii) 1.50% per year in relation to the Second Series Debentures; and (iii) 1.75% per year in relation to the Third Series Debentures. The payment of the remuneration of the Debentures will be made semiannually; and
- If certain targets for Biological Waste Management and Access to Healthcare are not met, through Saúde iD for patients from social classes C, D and E, as well as obligations associated with key sustainable performance indicators related to such goals are not met, within the terms established in the Indenture, the spreads referred to above will increase by up to (i) 0.125% per year in relation to the First Series Debentures; (ii) 0.25% per year in relation to the Second Series Debentures; and (iii) 0.35% per year in relation to the Third Series Debentures, pursuant to the Issuance Indenture.

More information on the Debentures can be found in the Minutes of the Board of Directors' Meeting, in the Indenture and in the Second Opinion report, available on the CVM website (<http://www.cvm.gov.br>) or on the Company's IR website (<http://ir.fleury.com.br/>).

São Paulo, July 12th, 2021

FERNANDO AUGUSTO RODRIGUES LEÃO FILHO

Chief Financial and Investor Relations Officer